Le Lézard
Classified in: Health
Subjects: PDT, FVT

Fortune Launches New Advice Column with Founder, Investor, Entrepreneur Andy Dunn


"Ask Andy" features tips for launching a new business venture while maintaining a healthy mind

Bonobos and Pie co-founder, best-selling author of "Burn Rate," and mental health advocate shares personal insights on mental health struggles as a business founder

NEW YORK, April 30, 2024 /PRNewswire/ -- Fortune Media announced today the launch of Ask Andy, a recurring advice column for entrepreneurs, founders and startup executives, written by Andy Dunn, co-founder of e-commerce pioneer Bonobos and an investor in and advisor to other startups. Dunn's column features invaluable advice and insights on how to scale startups and handle the stress that comes with launching and leading a business.

Ask Andy answers readers' questions about founding a business, building the right team, raising capital, maintaining mental health, and more. Ask Andy is the first advice column from Fortune that takes a personalized look at how to balance a startup while maintaining a strong body and mind.

Dunn, business investor, mental health advocate and current CEO of IRL social network creator Pie, is the author of Burn Rate: Launching a Startup and Losing My Mind, a memoir on mental illness and entrepreneurship. The 2022 best-seller candidly explored his struggle with building a business from scratch while wrestling with undiagnosed bipolar disorder. He recently wrote for Fortune on knowing when to quit your startup and admit failure. Ask Andy can be found bi-weekly on Fortune.com.

"It's been exciting to field questions from all the great founders and builders out there," says Dunn. "They're raising great points about company culture, balancing work and family, and dealing with the challenges of creating a company. Startup life can be the greatest thing AND one of the hardest things: I've been there, and I am loving the discussion and am learning as much from their questions as they may be from my 'answers'."

"Andy has built a wealth of experience as a startup and VC, all while being keenly aware of the mental and physical toll entrepreneurs pay on their journeys," says Fortune editor-in-chief Alyson Shontell. "We are thrilled Fortune readers can tap into his wisdom, candor, and humor."

(Have a question for Ask Andy? Send it to him here.)

Dunn will also be a co-chair of Fortune Brainstorm Tech 2024 Summit, July 15-17 in Park City, Utah, where he'll guide industry-leading conversations and bring Ask Andy live to the conference stage.

About Fortune
Fortune's mission is to change the world by making business better. We achieve that by providing trusted information, telling great stories, and building world-class communities. We measure performance by rigorous benchmarks, and we hold companies accountable. Our goal is to make Fortune a force for good through its second century and beyond. For more information, visit fortune.com.

Media Contacts:
Patrick Reilly
Fortune
[email protected]

Amy Galleazzi
[email protected]

SOURCE FORTUNE Media


These press releases may also interest you

at 02:05
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and...

at 01:18
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
. Hansa Biopharma, "Hansa" (STOCKHOLM: HNSA), today announced data featuring imlifidase will be presented at the American Transplant Congress (ATC), the joint annual meeting of the American Society of Transplant Surgeons (ASTS) and the American...

at 01:05
FDA Grants Breakthrough Therapy Designation to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with...

at 01:05
Innate Pharma: Clarification Regarding SAR443579 Designation
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by...

at 00:01
ZYMFENTRAtm (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance treatment through two years for adults with moderately to severely active Crohn's disease and ulcerative colitis
Celltrion USA announced today...

at 00:01
New Peer-Reviewed Clinical Studies Show SonarMD Reduces Emergency Department Visits and Hospitalizations for Patients with Ulcerative Colitis and Crohn's Disease
SonarMD today presented positive results from two large, longitudinal studies evaluating several major drivers of medical costs in people living with Inflammatory Bowel Disease (IBD) ? defined as people living with ulcerative colitis or Crohn's...

More news about Health...


News published on and distributed by: